Epilepsy Foundation Collaborating on Personalized Drug Discovery Platform for Epilepsy With Intellimedix and Pfizer Inc.

July 8, 2014

LANDOVER, MD, Jul 08, 2014 (Marketwired via COMTEX) -- The Epilepsy Foundation is developing a drug discovery platform for genetic forms of epilepsy in collaboration with Intellimedix and Pfizer Inc. The platform may help create individualized and potential new treatments for people living with Dravet Syndrome (a very severe type of genetic epilepsy) and other types of epilepsy for which limited treatment options are currently available.

"This collaboration has the potential to benefit all individuals and families living with epilepsy, especially the one-third of people with epilepsy who live with uncontrolled seizures despite all currently available therapies," said Philip M. Gattone, President and CEO of the Epilepsy Foundation. "With this drug discovery platform and our new collaboration, the Foundation furthers its mission to unify the epilepsy community and embrace innovation in new therapies."

"We are thrilled by this collaboration that aims to develop and apply novel drug screening technologies to deliver personalized therapies to patients with epilepsy," said Daniel Fischer, President & CEO of Intellimedix. "We will strive to significantly improve the lives of patients with Dravet Syndrome in the very short term."

"We are excited to be part of this collaboration because we believe that future therapies will be more tailored to an individual's needs," said Ruth McKernan, Head of Neusentis, Pfizer's research unit for pain and sensory disorders. "Collaborating with organizations like the Epilepsy Foundation is so important because they bring us closer to patients."

About Epilepsy

Epilepsy is a chronic neurological condition characterized by recurrent seizures. According to the CDC, epilepsy affects between 2.2 and 3 million people in the United States and, despite the availability of multiple anti-seizure drugs, one third of people with epilepsy still live with uncontrolled seizures.* Dravet Syndrome is a severe form of epilepsy for which no effective treatments exist.

About Intellimedix

Intellimedix is an innovative company that develops and applies state-of-the-art technologies to improve disease diagnostics, accelerate drug discovery, and personalize medicine. The company was founded by parents of children with epilepsy. For more information, visit www.intellimedix.com .

About the Epilepsy Foundation

The Epilepsy Foundation, a national non-profit with 48 affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation is an unwavering ally for individuals and families impacted by epilepsy and seizures. The mission of the Epilepsy Foundation is to stop seizures and sudden unexpected death in epilepsy (SUDEP), find a cure and overcome the challenges created by epilepsy through efforts including education, advocacy and research to accelerate ideas into therapies. The Foundation works to ensure that people with seizures have the opportunity to live their lives to their fullest potential. For additional information, please visit www.epilepsy.com .

*Institute of Medicine (U.S) Committee on the Public Health Dimensions of the Epilepsies. 2012. Epilepsy Across the Spectrum: Promoting Health and Understanding. "Overview of Epilepsy." Pgs. 33-38.

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.